Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for the 100mg and 200mg strengths of tramadol ER. [More]

Labopharm Inc. today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue, citing the potential benefit of its novel trazodone formulation, which contains Contramid(R). Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery. [More]

Biovail Corporation today announced financial results for the three-month and nine-month periods ended September 30, 2009. To the extent that this news release contains forward-looking statements, investors are cautioned that these statements are based on the Company’s current views, and actual outcomes are not certain. [More]

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and nine months ended September 30, 2009. [More]

Cipher Pharmaceuticals Inc. today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the United States District Court for the Eastern District of Virginia, for alleged infringement of two U.S. patents. The action relates to Cipher's New Drug Application ("NDA") filed with the U.S. Food and Drug Administration ("FDA") for CIP TRAMADOL ER, the Company's extended-release tramadol product. [More]

Labopharm Inc. today announced that its wholly owned subsidiary, Labopharm Europe Limited, has completed a distribution and supply agreement with Grunenthal GmbH for its twice-daily tramadol acetaminophen formulation for a number of countries in Europe. [More]

Labopharm Inc. today announced that it has been informed by Angelini, the manufacturer of the active pharmaceutical ingredient (API) for the Company's novel trazodone formulation, that it has received a letter from the U.S. Food and Drug Administration (FDA) stating that Angelini has appropriately addressed all deficiencies cited by the FDA following its inspection of the manufacturing facility in June and July of this year. [More]

Cipher Pharmaceuticals Inc. today announced that it has enrolled the first patient in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. [More]

Should you take opioid drugs for hip and knee pain caused by osteoarthritis? Probably not, suggests a new review of the best research on the subject. [More]

Labopharm Inc. today announced it has received notice from Sun Pharma Global FZE advising that Sun has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 100, 200 and 300 mg generic versions of Ryzolt(TM) (tramadol hydrochloride extended-release 100, 200 and 300 mg tablets) in the United States. [More]

The Association of American Universities (AAU), the Association of Public and Land-grant Universities (APLU), and The Science Coalition (TSC) today released highlighted examples of the important scientific work happening across the country as a result of the American Recovery and Reinvestment Act of 2009 (ARRA). The brief report summarizes just a handful of the thousands of projects benefiting from stimulus dollars. [More]

Labopharm Inc. today announced that three separate posters will be presented at three upcoming internationally prestigious medical meetings showcasing data on its novel trazodone formulation. [More]

Many Americans unfortunately do not have health insurance, leading to unaffordable bills at the doctor's office and pharmacy. Uninsured Americans don't have to pay sky high out-of-pocket costs for prescription drugs however with OnlineUSHealth.com, a leading online pharmacy where customers can buy online prescription drugs quickly, easily and inexpensively. [More]

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the U.S. Food and Drug Administration (FDA) has accepted Labopharm's response regarding its novel formulation of the antidepressant trazodone as complete and designated it as a Class 2 resubmission. The FDA has assigned Labopharm a new Prescription Drug User Fee Act (PDUFA) action date of February 11, 2010. [More]

Labopharm Inc. today commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products L.P. against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are owned by Purdue and are licensed to Ortho-McNeil, Inc., the marketer of Ultram(R) ER. [More]